Abstract
New studies further demonstrate that lowering low-density lipoprotein (LDL)-cholesterol, at least with the use of statins, decreases the risk of cardiovascular disease (CVD). Subsequently national and international guidelines have set target levels for LDLcholesterol that are progressively lower, making the likelihood of patients attaining them progressively more limited, even with the use of all currently available medications. Thus, there is a clear need for new therapeutic approaches to lower LDL-cholesterol. Antisense oligonucleotides (ASO) represent a new paradigm for the discovery of potentially powerful and selective drugs with a mechanism of action based on the concept of base-pair hybridization as described by Watson and Crick, resulting in decreased production of target proteins. In mouse and human genetic models it has been shown that decreasing hepatic apolipoprotein B-100 (ApoB-100) as well as proprotein convertase subtilisin/kexin type 9 (PCSK9) production is associated with lower circulating LDL-cholesterol levels. Purpose of this review is to discuss the available data on the effects of various ASO used for the treatment of dyslipidemia, with the main focus on ASO against ApoB-100, the most advanced in clinical development, and on PCSK9.
Keywords: ApoB, LDL-cholesterol, Antisense oligonucleotides, Mipomersen, PCSK9, Hyperlipidemia, hybridization, kexin, apolipoproteins, immunoassays, cytosine, thymine, guanine, adenine, uracil, deoxyribonucleotides, heteroduplex, thrombocytopenia, gapmer, morpholino, colesevelam
Current Pharmaceutical Design
Title: Antisense Oligonucleotides for the Treatment of Dyslipidemia
Volume: 17 Issue: 9
Author(s): I. Gouni-Berthold and H. K. Berthold
Affiliation:
Keywords: ApoB, LDL-cholesterol, Antisense oligonucleotides, Mipomersen, PCSK9, Hyperlipidemia, hybridization, kexin, apolipoproteins, immunoassays, cytosine, thymine, guanine, adenine, uracil, deoxyribonucleotides, heteroduplex, thrombocytopenia, gapmer, morpholino, colesevelam
Abstract: New studies further demonstrate that lowering low-density lipoprotein (LDL)-cholesterol, at least with the use of statins, decreases the risk of cardiovascular disease (CVD). Subsequently national and international guidelines have set target levels for LDLcholesterol that are progressively lower, making the likelihood of patients attaining them progressively more limited, even with the use of all currently available medications. Thus, there is a clear need for new therapeutic approaches to lower LDL-cholesterol. Antisense oligonucleotides (ASO) represent a new paradigm for the discovery of potentially powerful and selective drugs with a mechanism of action based on the concept of base-pair hybridization as described by Watson and Crick, resulting in decreased production of target proteins. In mouse and human genetic models it has been shown that decreasing hepatic apolipoprotein B-100 (ApoB-100) as well as proprotein convertase subtilisin/kexin type 9 (PCSK9) production is associated with lower circulating LDL-cholesterol levels. Purpose of this review is to discuss the available data on the effects of various ASO used for the treatment of dyslipidemia, with the main focus on ASO against ApoB-100, the most advanced in clinical development, and on PCSK9.
Export Options
About this article
Cite this article as:
Gouni-Berthold I. and K. Berthold H., Antisense Oligonucleotides for the Treatment of Dyslipidemia, Current Pharmaceutical Design 2011; 17 (9) . https://dx.doi.org/10.2174/138161211795428830
DOI https://dx.doi.org/10.2174/138161211795428830 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Immune-Inflammatory Activation in Acute Coronary Syndromes: A Look into the Heart of Unstable Coronary Plaque
Current Cardiology Reviews The Role of Coagulation and Fibrinolysis in the Pathogenesis of Acute Lung Injury
Current Respiratory Medicine Reviews Nucleic Acid Drugs for Preventing Restenosis after Coronary Revascularization
Current Topics in Medicinal Chemistry Fetal Mechanisms That Lead to Later Hypertension
Current Drug Targets Artificial Intelligence Approaches for Rational Drug Design and Discovery
Current Pharmaceutical Design Imaging of Visceral Adipose Tissue: An Emerging Diagnostic Tool and Therapeutic Target
Current Drug Targets - Cardiovascular & Hematological Disorders Insights into Immunophilin Structure and Function
Current Medicinal Chemistry Adherence to Secondary Prophylaxis for Acute Rheumatic Fever and Rheumatic Heart Disease: A Systematic Review
Current Cardiology Reviews General or Local Anesthesia for TAVI? A Systematic Review of the Literature and Meta-Analysis
Current Pharmaceutical Design Increased Exercise Favorably Modifies Coronary Artery Disease and Peripheral Arterial Disease Outcomes
Current Vascular Pharmacology Pleiotropic Effects of Fenofibrate
Current Pharmaceutical Design Interaction of the Heart and Lungs During Exercise: Physiology and Pathophysiology in Children with Congenital Heart Disease
Current Respiratory Medicine Reviews Randomized, Placebo Controlled Study of the Effects of Etoricoxib on Markers of Inflammation, Pain and Muscle Force After Eccentric Exercise
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Glutathione Peroxidase: A Potential Marker for the Most Common Diseases and Disorders
Recent Patents on Biomarkers Cardiac Imaging in Heart Failure with Comorbidities
Current Cardiology Reviews Detection of Ventricular Arrhythmias using HRV Analysis and Quadratic Features
Recent Advances in Electrical & Electronic Engineering The Role of Neuropeptides and Neurohormones in Neurogenic Cardiac Arrhythmias
Current Drug Targets - Cardiovascular & Hematological Disorders Pharmacogenetics of the Metabolic Disturbances and Atherosclerosis Associated with Antiretroviral Therapy in HIV-Infected Patients
Current Pharmaceutical Design Novel Therapeutic Strategy in the Management of COPD: A Systems Medicine Approach
Current Medicinal Chemistry NPY Y1 and Y5 Receptor Selective Antagonists as Anti-Obesity Drugs
Current Topics in Medicinal Chemistry